Based on the Axogen Inc stock forecast from 3 analysts, the average analyst target price for Axogen Inc is USD 16.00 over the next 12 months. Axogen Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Axogen Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Axogen Inc’s stock price was USD 12.64. Axogen Inc’s stock price has changed by -0.16% over the past week, -11.92% over the past month and +119.44% over the last year.
No recent analyst target price found for Axogen Inc
No recent average analyst rating found for Axogen Inc
Company Overview Axogen Inc
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida. Address: 13631 Progress Boulevard, Alachua, FL, United States, 32615 Read Less
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging sever...Read More
Frequently Asked Questions About Axogen Inc (AXGN) Stock
Based on ratings from 3 analysts Axogen Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on AXGN's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for AXGN is USD 16.00 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 13.
Unfortunately we do not have enough data on AXGN's stock to indicate if its overvalued.
The last closing price of AXGN's stock was USD 12.64.
The most recent market capitalization for AXGN is USD 0.55B.
Based on targets from 3 analysts, the average taret price for AXGN is projected at USD 16.00 over the next 12 months.
This means that AXGN's stock price may go up by +26.58% over the next 12 months.
We can't find any ETFs which contains Axogen Inc's stock.
As per our most recent records Axogen Inc has 426 Employees.
Axogen Inc's registered address is 13631 Progress Boulevard, Alachua, FL, United States, 32615.
You can get more information about it from Axogen Inc's website at https://www.axogeninc.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Axogen Inc (AXGN) Stock
Based on ratings from 3 analysts Axogen Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on AXGN's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for AXGN is USD 16.00 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 13.
Unfortunately we do not have enough data on AXGN's stock to indicate if its overvalued.
The last closing price of AXGN's stock was USD 12.64.
The most recent market capitalization for AXGN is USD 0.55B.
Based on targets from 3 analysts, the average taret price for AXGN is projected at USD 16.00 over the next 12 months.
This means that AXGN's stock price may go up by +26.58% over the next 12 months.
We can't find any ETFs which contains Axogen Inc's stock.
As per our most recent records Axogen Inc has 426 Employees.
Axogen Inc's registered address is 13631 Progress Boulevard, Alachua, FL, United States, 32615.
You can get more information about it from Axogen Inc's website at https://www.axogeninc.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AXGN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
